United States Tissue Engineered - Skin Substitutes Market Outlook to 2024

2017-09-04
Price :
Published : Sep-2017
No. of Pages : 71
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Introduction 5
2.1 What Is This Report About? 5
2.2 Tissue Engineered - Skin Substitutes Market Segmentation 5
2.3 Definitions of Markets Covered in the Report 6
3 Tissue Engineered - Skin Substitutes Market, United States 7
3.1 Tissue Engineered - Skin Substitutes Market, United States, Revenue ($m), 2010-2017 7
3.2 Tissue Engineered - Skin Substitutes Market, United States, Revenue ($m), 2017-2024 9
3.2.1 Biologic Skin Substitutes Market, United States, Revenue ($m), by Segment, 2010-2017 11
3.2.2 Biologic Skin Substitutes Market, United States, Revenue ($m), by Segment, 2017-2024 13
3.3 Tissue Engineered - Skin Substitutes Market, United States, Volume (Units), 2010-2017 15
3.4 Tissue Engineered - Skin Substitutes Market, United States, Volume (Units), 2017-2024 17
3.4.1 Biologic Skin Substitutes Market, United States, Volume (Units), by Segment, 2010-2017 19
3.4.2 Biologic Skin Substitutes Market, United States, Volume (Units), by Segment, 2017-2024 21
3.5 Tissue Engineered - Skin Substitutes Market, United States, Average Price ($), 2010-2024 23
3.6 Tissue Engineered - Skin Substitutes Market, United States, Distribution Share by Revenue ($m), 2017 24
3.7 Tissue Engineered - Skin Substitutes Market, United States, Company Share by Revenue ($m), 2017 25
4 Overview of Key Companies in United States, Tissue Engineered - Skin Substitutes Market 27
4.1 Ethicon US LLC 27
4.1.1 Company Overview 27
4.2 Baxter International Inc 27
4.2.1 Company Overview 27
4.3 C. R. Bard Inc 27
4.3.1 Company Overview 27
4.4 CryoLife Inc 28
4.4.1 Company Overview 28
4.5 Integra LifeSciences Corp 28
4.5.1 Company Overview 28
5 Tissue Engineered - Skin Substitutes Market Pipeline Products 29
6 Financial Deals Landscape 30
6.1 Acquisition 30
6.1.1 Allergan Acquires LifeCell from Acelity for USD2.9 Billion 30
6.2 Equity Offerings 32
6.2.1 RenovaCare Raises USD1 Million in Private Placement of Units 32
6.2.2 Biostage Raises USD8 Million Public Offering of Shares 33
6.3 Partnerships 34
6.3.1 Progenerative Medical Enters into Licensing Agreement with Kinetic Concepts 34
6.4 Venture Financing 35
6.4.1 Saba Labs Raises USD0.3 Million in Venture Financing 35
6.4.2 Organogenesis Raises USD20 Million in Venture Financing 36
7 Recent Developments 37
7.1 Corporate Communications 37
7.1.1 Jul 27, 2017: Anika Announces Appointment of Joseph Darling as President 37
7.1.2 Jun 09, 2017: Acera Surgical appoints new board member 37
7.1.3 Apr 18, 2017: Biostage Appoints Stephen F. Badylak DVM, PhD, MD, as Co-Chairman of Scientific Advisory Board 38
7.1.4 Mar 19, 2017: MiMedx Announces The Addition Of Luis A. Aguilar To Its Board Of Directors 38
7.1.5 Sep 19, 2016: Organogenesis Announces New Chief Financial Officer 39
7.2 Financial Announcements 40
7.2.1 Aug 14, 2017: Biostage Reports 2017 Second Quarter Financial Results 40
7.2.2 Jul 26, 2017: MiMedx Announces Record Results For The Second Quarter Of 2017 And Raises Full Year Revenue Guidance 41
7.2.3 Jul 26, 2017: Anika Reports Strong Second Quarter 2017 Financial Results 43
7.2.4 Jul 13, 2017: MiMedx Announces that its Second Quarter Revenue Exceeds the Guidance Range 44
7.2.5 May 11, 2017: Biostage Reports 2017 First Quarter Financial Results and Provides Business Update 45
7.2.6 May 03, 2017: Anika Reports First Quarter 2017 Financial Results 46
7.2.7 Apr 28, 2017: MiMedx Announces Record Results For First Quarter Of 2017 47
7.2.8 Apr 13, 2017: MiMedx Announces First Quarter 2017 Revenue to Exceed High End of Guidance 49
7.2.9 Mar 09, 2017: Biostage Reports 2016 Financial Results and Provides Business Update 49
7.2.10 Feb 23, 2017: MiMedx Announces 2016 Record Results 51
7.2.11 Feb 15, 2017: Anika Reports Fourth Quarter and Full Year 2016 Financial Results 53
7.2.12 Feb 15, 2017: Anika Therapeutics Reports 33% Revenue Growth in Third Quarter 2011 53
7.2.13 Jan 09, 2017: MiMedx Fourth Quarter 2016 Revenue in Upper Range of Guidance 54
7.2.14 Dec 16, 2016: MiMedx 2017 Guidance Forecasts Revenue Growth In Excess Of 21% And Operating Earnings Growth In Excess Of 90% 56
7.2.15 Nov 10, 2016: Biostage Reports 2016 Third Quarter Financial Results and Provides Business Update 57
7.2.16 Oct 27, 2016: MiMedx Announces Third Quarter 2016 Results 58
7.2.17 Oct 26, 2016: Anika Reports Third Quarter 2016 Financial Results 60
7.2.18 Oct 10, 2016: MiMedx Third Quarter 2016 Revenue Exceeds Upper End of Guidance 61
7.3 Other Significant Developments 62
7.3.1 Jul 05, 2017: MiMedx Agreement With AvKARE Expires As Planned Following Completion Of Contract Wind-Down 62
7.3.2 Sep 06, 2016: MiMedx Reaffirms Q3 and Full Year 2016 Guidance 62
7.4 Product News 63
7.4.1 Nov 03, 2016: MiMedx Announces USP-NF Monograph For dHACM Allografts Has Published 63
7.4.2 Sep 12, 2016: Scientific Study Confirms How MiMedx dHACM Allografts Effectively Promote Wound Repair 63
8 Appendix 65
8.1 Research Methodology 66
8.1.1 Coverage 66
8.1.2 Secondary Research 66
8.1.3 Primary Research 67
8.1.4 Market Modeling and Forecasting 68
8.1.5 Company Share Analysis 69
8.1.6 Distribution Share Analysis 70
8.1.7 Benchmarking 70
8.2 GlobalData Consulting 70
8.3 Contact Us 71
8.4 Disclaimer 71

1.1 List of Tables
Table 1: Tissue Engineered - Skin Substitutes Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 8
Table 2: Tissue Engineered - Skin Substitutes Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 10
Table 3: Biologic Skin Substitutes Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 12
Table 4: Biologic Skin Substitutes Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 14
Table 5: Tissue Engineered - Skin Substitutes Market, United States, Volume (Units), Historic, 2010-2017 16
Table 6: Tissue Engineered - Skin Substitutes Market, United States, Volume (Units), Forecast, 2017-2024 18
Table 7: Biologic Skin Substitutes Market, United States, Volume (Units), Historic, 2010-2017 20
Table 8: Biologic Skin Substitutes Market, United States, Volume (Units), Forecast, 2017-2024 22
Table 9: Tissue Engineered - Skin Substitutes Market, United States, Average Price ($) Historic, 2010-2017 23
Table 10: Tissue Engineered - Skin Substitutes Market, United States, Average Price ($), Forecast, 2017-2024 23
Table 11: Tissue Engineered - Skin Substitutes Market, United States, Distribution Share by Revenue ($m), USD Constant, 2017 24
Table 12: Tissue Engineered - Skin Substitutes Market, United States, Company Share by Revenue ($m), USD Constant, 2017 26
Table 13: Tissue Engineered - Skin Substitutes Market Pipeline Products 29
Table 14: Allergan Acquires LifeCell from Acelity for USD2.9 Billion 30
Table 15: RenovaCare Raises USD1 Million in Private Placement of Units 32
Table 16: Biostage Raises USD8 Million Public Offering of Shares 33
Table 17: Progenerative Medical Enters into Licensing Agreement with Kinetic Concepts 34
Table 18: Saba Labs Raises USD0.3 Million in Venture Financing 35
Table 19: Organogenesis Raises USD20 Million in Venture Financing 36
Table 20: Total Number of Primary Research Participants, Wound Care Management Market, by Country 68

1.2 List of Figures
Figure 1: Tissue Engineered - Skin Substitutes Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 7
Figure 2: Tissue Engineered - Skin Substitutes Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 9
Figure 3: Biologic Skin Substitutes Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 11
Figure 4: Biologic Skin Substitutes Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 13
Figure 5: Tissue Engineered - Skin Substitutes Market, United States, Volume (Units), Historic, 2010-2017 15
Figure 6: Tissue Engineered - Skin Substitutes Market, United States, Volume (Units), Forecast, 2017-2024 17
Figure 7: Biologic Skin Substitutes Market, United States, Volume (Units), Historic, 2010-2017 19
Figure 8: Biologic Skin Substitutes Market, United States, Volume (Units), Forecast, 2017-2024 21
Figure 9: Tissue Engineered - Skin Substitutes Market, United States, Company Share (%) 2017 25
Filed in: Medical Device
Publisher : GlobalData